MiMedx Launches G4Derm Plus Nationwide, Secures Premier and Vizient GPO Agreements
MiMedx launched G4Derm Plus, a 510(k)-cleared acellular flowable ECM using self-assembling peptides, with initial sales delivered nationwide. It secured Premier and Vizient GPO agreements for national distribution, expanding its surgical wound-care portfolio.
1. Product Launch and Initial Sales
MiMedx announced the commercial launch of G4Derm Plus and has already delivered initial orders nationwide after acquiring exclusive U.S. distribution rights for the product.
2. Innovative Peptide Technology
G4Derm Plus features a self-assembling peptide matrix that forms a three-dimensional biomimetic scaffold to promote revascularization, granulation tissue growth and reepithelialization while inhibiting bacterial contamination.
3. GPO Agreements Expand Distribution
The company secured group purchasing agreements with Premier and Vizient, enabling G4Derm Plus to be distributed across participating hospital networks and strengthening its presence in surgical wound management.